Literature DB >> 1667754

Use of pentoxifylline as an inhibitor of free radical generation in peripheral vascular disease. Results of a double-blind placebo-controlled study.

G Ciuffetti1, M Mercuri, C Ott, R Lombardini, R Paltriccia, G Lupattelli, L Santambrogio, E Mannarino.   

Abstract

The effects of an infusion of pentoxifylline 1 g as an inhibitor of free radical generation have been determined in a double-blind placebo-controlled study. Leucocyte-derived free radical generation (by the superoxide dismutase-inhibitable reduction of ferricytochrome), the release of reactive oxygen metabolites (as plasma oxidant activity), unfractionated leucocyte and erythrocyte filterability rates (using a constant-flow positive-pressure system), plasma viscosity, and plasma fibrinogen concentration have been measured in two matched groups of 10 patients with Stage II peripheral vascular disease, before and after treatment. Transcutaneous oxygen pressure (PtcO2) during treadmill exercise to stress leg circulation was also measured. Leucocyte-derived free radicals were generated during peripheral ischaemia. Pentoxifylline inhibited their generation, blocked the release of reactive oxygen metabolites, and reduced impairment of the filterability rate of unfractionated leucocytes. The improvements were accompanied by significant shortening of the half-time of recovery of transcutaneous oxygen pressure, indicating that ischaemic damage had been contained.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1667754     DOI: 10.1007/BF00314976

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  23 in total

1.  Reactive oxygen metabolites in peripheral arterial occlusive disease.

Authors:  G Ciuffetti; E Mannarino; M Mercuri; L Pasqualini; R Lombardini; C Ott; G Lupattelli; R Paltriccia
Journal:  Vasa       Date:  1990       Impact factor: 1.961

2.  The adrenochrome pathway: the major route for adrenalin catabolism by polymorphonuclear leucocytes.

Authors:  S B Matthews; A H Henderson; A K Campbell
Journal:  J Mol Cell Cardiol       Date:  1985-04       Impact factor: 5.000

Review 3.  Peripheral vascular disease.

Authors:  E Ernst
Journal:  BMJ       Date:  1989-10-07

4.  Immunochemical quantitation of antigens by single radial immunodiffusion.

Authors:  G Mancini; A O Carbonara; J F Heremans
Journal:  Immunochemistry       Date:  1965-09

5.  Hemorheological effects of pentoxifylline on disturbed flow behavior of blood in patients with cerebrovascular insufficiency.

Authors:  E Ott; H Lechner; F Fazekas
Journal:  Eur Neurol       Date:  1983       Impact factor: 1.710

6.  Effect of pentoxifylline on microvascular blood flow velocity.

Authors:  N Ohshima; M Sato
Journal:  Angiology       Date:  1981-11       Impact factor: 3.619

7.  Effects of preparative procedures and of cell activation on flow of white cells through micropore filters.

Authors:  G B Nash; J G Jones; J Mikita; B Christopher; J A Dormandy
Journal:  Br J Haematol       Date:  1988-10       Impact factor: 6.998

8.  The adrenochrome pathway. A potential catabolic route for adrenaline metabolism in inflammatory disease.

Authors:  S B Matthews; M B Hallett; A H Henderson; A K Campbell
Journal:  Adv Myocardiol       Date:  1985

9.  Influence of risk factors and coagulation phenomena on the fluidity of blood in chronic arterial occlusive disease.

Authors:  B Angelkort; H Kiesewetter
Journal:  Scand J Clin Lab Invest Suppl       Date:  1981

10.  Chemotactic factor enhancement of superoxide release from fluoride and phorbol myristate acetate stimulated neutrophils.

Authors:  D English; J S Roloff; J N Lukens
Journal:  Blood       Date:  1981-07       Impact factor: 22.113

View more
  12 in total

1.  Pentoxifylline in arterial disease of the legs.

Authors:  R Verhaeghe; M Verstraete
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

2.  Pentoxifylline attenuates ischemia/reperfusion injury to the small intestine in the rat.

Authors:  R Udassin; A Vromen; D Seror; Y Haskel
Journal:  Pediatr Surg Int       Date:  2013-09-21       Impact factor: 1.827

Review 3.  Looking beyond the ovary for oncofertility care in women: uterine injury as a potential target for fertility-preserving treatments.

Authors:  D Garg; E B Johnstone; L Lomo; D B Fair; M P Rosen; R Taylor; B Silver; J M Letourneau
Journal:  J Assist Reprod Genet       Date:  2020-04-28       Impact factor: 3.412

Review 4.  Intermittent claudication: new targets for drug development.

Authors:  Eric P Brass
Journal:  Drugs       Date:  2013-07       Impact factor: 9.546

5.  Tumor necrosis factor-alpha-induced inhibition of phosphatidylcholine synthesis by human type II pneumocytes is partially mediated by prostaglandins.

Authors:  J Arias-Díaz; E Vara; C García; J L Balibrea
Journal:  J Clin Invest       Date:  1994-07       Impact factor: 14.808

Review 6.  Pentoxifylline for intermittent claudication.

Authors:  Kareem Salhiyyah; Rachel Forster; Eshan Senanayake; Mohammed Abdel-Hadi; Andrew Booth; Jonathan A Michaels
Journal:  Cochrane Database Syst Rev       Date:  2015-09-29

Review 7.  Pentoxifylline (oxpentifylline). A review of its therapeutic efficacy in the management of peripheral vascular and cerebrovascular disorders.

Authors:  J E Frampton; R N Brogden
Journal:  Drugs Aging       Date:  1995-12       Impact factor: 3.923

Review 8.  A review of the potential protective effects of pentoxifylline against drug-induced nephrotoxicity.

Authors:  Zahra Nasiri-Toosi; Simin Dashti-Khavidaki; Hossein Khalili; Mahboob Lessan-Pezeshki
Journal:  Eur J Clin Pharmacol       Date:  2012-11-22       Impact factor: 2.953

9.  Pentoxifylline for intermittent claudication.

Authors:  Cathryn Broderick; Rachel Forster; Mohammed Abdel-Hadi; Kareem Salhiyyah
Journal:  Cochrane Database Syst Rev       Date:  2020-10-16

10.  Beneficial effect of pentoxifylline into the testis of rats in an experimental model of unilateral hindlimb ischemia/reperfusion injury.

Authors:  Mohammad Ashrafzadeh Takhtfooladi; Fariborz Moayer; Hamed Ashrafzadeh Takhtfooladi
Journal:  Int Braz J Urol       Date:  2015 May-Jun       Impact factor: 1.541

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.